MedTrace Logo

Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.

NCT01950286 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2013-09-25

No results posted yet for this study

Summary

Hyper-CVAD (a chemotherapy regimen) has shown promising results in adult T-cell Acute Lymphoblastic Leukemia (T-ALL). Patients with T-ALL diagnosis were reported to the Swedish Adult Acute Leukemia Registry between October 2002 and September 2006. Hyper-CVAD was recommended to all patients without severe comorbidity. Allogeneic stem cell transplantation was recommended for patients with high-risk disease. The aim of this population-based study was to assess the efficacy of Hyper-CVAD treatment.

Conditions

  • T-cell Acute Lymphoblastic Leukemia

Sponsors & Collaborators

  • Region Örebro County

    lead OTHER

Principal Investigators

  • Piotr Kozlowski, MD · Orebro University Hospital, Orebro University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2013-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01950286 on ClinicalTrials.gov